U.S. drug overdose has been reduced by 15 months, destroying death spiral

The U.S. drug overdose crisis has entered unknown territory.

Overdose deaths have declined for 15 consecutive months for decades, the longest-lasting decline since the crisis began. But this encouraging shift obscures an unsettling reality: the decline does not reach all equally. While the total death toll in August 2023 ranged from 33.24 per 100,000 people per 100,000 people to 24.29 per 100,000 in October 2024, some communities continue to experience an increase in mortality rates, revealing how addiction treatment and harm reduction reach the ongoing gap across populations.

The new analysis, published on JAMA Network Open, examined 800,645 overdose deaths from January 2015 to October 2024, and provided the most detailed picture of when and where to begin turning the trend in the deadliest drug crisis in the United States.

No one sees the turning point

August 2023 marks a statistical turning point determined by researchers using complex trend analysis. That month, the ruthless rise in excessive death finally turned around due to reasons still under investigation.

The decline accelerated sharply in February 2024. The mortality rate began to drop rapidly, with a 0.84 per month dropping by 0.36 per month compared to the rate of 0.84 per month per month. This sharp decline continued until October 2024, which is the latest data.

What makes this drop particularly amazing is its speed. The current rate of decline is almost double the previous surge between 2019 and 2021, when the death toll increased by 0.46 per month.

Numbers are found by key:

• From August 2023 to October 2024, it has been down for 15 consecutive months.
• Overall mortality rate dropped from 33.24 to 24.29 per 100,000 people
• Opioid deaths drop rapidly than irritant-related deaths
• Northeast and Midwest regions have restored pandemic levels
• Adults over 55 years old and several ethnic groups are still increasing

Restore geography

The crisis didn’t start anywhere immediately, nor was it recovery. The Northeast, Midwest and Southern regions all peaked in October 2022, a full year of national average. The West lags behind and does not reach its peak until October 2023.

This geographical difference reflects the complex supply chains driving the U.S. overdose crisis. Fentanyl first arrived in East Coast cities in 2014, from Maine to devastating communities in Virginia. The deadly synthetic opioids take longer to penetrate the Western drug market, which explains why the region has since peaked and still maintains the highest death rate nationwide.

By the end of 2024, the Northeast had the lowest rate of overdose since 2015. The Midwest has returned to 2018 levels. However, Westerners are still elevated in some states (Nawada, Utah and Alaska) but still experience accelerated mortality rates.

Why do some areas recover faster than others? The answer may involve multiple factors: Early exposure to fentanyl may have claimed to be the most vulnerable user, while treatment infrastructure and injury reduction programs expand faster in tough Eastern communities.

The burden of inequality of progress

Perhaps the most concerned finding involves who is, rather than overall decline. Despite the huge improvements in young people, nearly five deaths per 100,000 people a year ago have continued to increase for the ninth consecutive year for young people aged 25-34.

Racial differences tell an equally complex story. American Indians or Alaska natives had the highest death rate in 2023, at 38.45 per 100,000, although the pace of growth slowed significantly from the peak in 2021. In 2023, the Black or African American community had the highest death rate, with 48.88 per 100,000 people per 100,000 people.

These patterns suggest that although the overall crisis may be weakening, it continues to spread to the communities that were initially affected. This reflects historical patterns in drug epidemics, at different times, substances and their consequences move through different populations.

Opioid irritating cleavage

One key insight that distinguishes this study involves different pathways for different drug types. Opioid-related deaths (mainly driven by fentanyl) are much faster than irritant-related deaths involving cocaine and methamphetamine.

After August 2023, opioid deaths fell by 0.80 times a month, while methamphetamine deaths fell by only 0.25 per 100,000 times, and cocaine deaths were only 0.07 per 100,000. This suggests that the mechanism driving the decline may be specific to opioids rather than representing a wide range of drug-related mortality reductions.

The researchers used connection point regression analysis, a statistical technique that determines the exact moment of the trend shifting direction. Unlike simple comparisons over the year, this method can distinguish temporary fluctuations from continuous changes in trajectory.

What drove the decline?

The researchers have proposed some explanations to continue to decline, although the determined answers remain elusive. One possibility involves what epidemiologists call the “cohort effect,” a grim reality that many of the most vulnerable people may have died, narrowing down the high-risk population.

Hazard reduction efforts may work. Extended naloxone access makes overdose resistant drugs widely available. Changes in drug use patterns, such as increasing numbers of people smoking instead of injecting fentanyl, may reduce the risk of fatal overdose.

Changes in drug supply provide another explanation. The composition of street medicines has evolved, like lignazine, a veterinary sedative, found to appear along with fentanyl. Although lignazine can produce serious medical complications, it may reduce immediate overdose death by affecting how people respond to opioids.

Therapeutic access has been greatly expanded. Drug-assisted treatment programs use drugs such as buprenorphine and methadone to help people become addicted, and are growing in many communities.

The method behind the numbers

The advantage of this study is its comprehensive approach to analyzing overdose trends. Instead of relying on simple death counts, the researchers used population data to calculate monthly mortality rates to illustrate population changes over time.

They analyzed the moving averages over the 12-month period to smooth out seasonal variations – winter usually drops in winter and summer. This approach reveals real trend changes that normal seasonal fluctuations may mask.

The team used medical examiner regulations to examine deaths involving specific drug types, allowing them to track the different contributions of opioids, cocaine and methamphetamine to overall mortality patterns.

Cautious optimism

While the continued decline brings hope, researchers emphasize caution. The current mortality rate is still at a crisis level, above any reasonable threshold for public health emergencies. The 24.29 deaths per 100,000 recorded in October 2024 still represent a catastrophic mortality rate.

Throughout the crisis, a shorter decline occurred, including seven separate periods that lasted for at least three months. The current decline is noteworthy of its duration and acceleration, which suggests that something more basic may have changed.

The increased persistent signals among older people and certain ethnic groups suggest that the crisis continues to spread to the initially affected populations. This model requires targeted interventions rather than universal approaches.

expect

Understanding why excessive death is falling and why decline is not a common cause is crucial to maintaining progress. Geographic and demographic changes show that effective interventions exist but do not reach all affected communities equally.

Opioid deaths are faster than irritating deaths, suggesting that different substances may require different intervention strategies. Naloxone effectively reverses opioid overdose, but there is no equivalent for drug with methamphetamine or cocaine overdose.

As this crisis develops, the challenge shifts from simply reducing overall numbers to ensuring that all communities benefit from any factor-driven decline. The goal is not only the target of death, but the number of deaths has decreased.

Data suggest that the United States may be emerging from the worst drug crisis in its history. However, the work of understanding the reasons and ensuring progress for all populations is just beginning.

Related